Novo Silico for Biopharma Projects…
Your Situation: Human longevity is constrained. Constraints include cardiovascular and neurodegenerative diseases and many types of cancer. Developing targeted therapies against such diseases requires substantial dedicated resources over several years and bears attrition risk throughout the entire development cycle. The challenging cost and risk profile of biopharmaceutical development, in particular during clinical trials, is limiting R&D capacities and constraining capabilities.
Our Proposal: We propose an affordable R&D capability enhancement, exploring a larger space of potential therapies in less time with given resources, combined with earliest-possible indication of pre-clinical or clinical attrition. Such new capability is driven by the progressing analytical, predictive and generative power and accuracy of bioinformatics. With novel proprietary algorithms, we are able to…
- … design complex therapeutic molecules of increasing strength, versatility and selectivity;
- … validate their on-target affinity, specificity and robustness with higher accuracy;
- … simulate their ADME life cycle in the human body at higher level of detail;
- … reduce remaining attrition risk in pre-clinical, clinical and approval stages to a minimum.
Based on our proprietary software, we are currently augmenting therapy development projects in silico in their exploratory and pre-clinical phases. Through ambitious, automated multicriteria screening and selection, we are further minimizing attrition risk of subsequent clinical and approval phases.
